Latest news with #AnjaleeKhemlani
Yahoo
21 hours ago
- Business
- Yahoo
Trump admin. cancels Moderna bird fu vaccine contract
The Trump administration has canceled a contract with Moderna (MRNA) worth hundreds of millions of dollars. The contract was supposed to help Moderna develop a vaccine for humans to defend against bird flu. Yahoo Finance Senior Health Care Reporter Anjalee Khemlani reports the details in the video above. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Trump administration canceling more than $700 million awarded to drug maker Moderna to develop the vaccine against potential pandemic viruses. For more we're bringing in here Yahoo Finance Senior Health Reporter, Angeli Kamani. Ange. Yeah, like you mentioned, the NIH canceled more than $750, a million dollars, rather, in funding for Moderna. And this is something that the company found out just based on a notification to themselves, even though they were really expecting that to get into late stage development. They said in a statement, Moderna received notice that the Health and Human Services Department, remember led by Secretary Robert F. Kennedy will terminate the award for the late stage development and rights to purchase the pre-pandemic influenza vaccines. Now, we went out to HHS to understand what their rationale was behind this. And among other things they mentioned that the MRNA technology remains quote, "under tested" and we are not going to spend taxpayer dollars repeating the mistakes of the last administration which concealed legitimate safety concerns from the public. And in that they're referring to the myocarditis that was evident in some males and some younger individuals. So, this is really just the latest setback for the company. We know it's been pummeled, the stock is down more than 30% on the year. This is one of the latest. So, we know that they pulled their filing of a combination flu and COVID vaccine earlier last week. Then we've got the NIH funding that's cutting the pandemic and bird flu. And then we've also got missing the Q1 estimates earlier this year. So, just really telling a really hard story for this company. We know it's been under pressure because of the waning COVID revenues, and these are just some of those areas that were supposed to sort of plug that hole. And now, without those in the way, it's a question on what Moderna's viability is. Now, on the flip side, you do have some good news, right? The company's still working on a number of clinical trials with Merck on cancer vaccine. It also has a partnership with Vertex on cystic fibrosis. So, they do have a few other things going for them, but this is really a longer play for the company rather than any near term that they would have otherwise been able to take advantage of. All right. Thanks, Angeli. Appreciate it. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Regeneron stock sinks over trial data for smoker's lungs drug
Regeneron Pharmaceuticals (REGN) shares sank in Friday trading after the company published disappointing drug trial results for a treatment on a condition called smoker's lungs. The drug was co-developed with Sanofi (SNY, Yahoo Finance senior health reporter Anjalee Khemlani comes on Market Domination Overtime to speak more on this. Regeneron has put up a bid to acquire genetic testing firm 23andMe (ME) after the company filed for bankruptcy. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Well shares of Regeneron Pharmaceuticals, they're sinking. The move lower comes as trial results for the company's co-developed experimental drug with Sanofi disappoints. Joining us now with more is Yahoo Finance's, Angelique Clamontange. That's right, Josh. They got news of uh, the drug not necessarily meeting the end points that it was supposed to. The stock down about 19%, uh closing at that rate today. And we saw that this is a drug that the company had uh, had co-developed with Sanofi and it's supposed to address chronic obstructive pulmonary disease and they're looking at former smokers who have basically inflammation or damage to their lung tissue, making it harder to breathe. Now the primary endpoint of reducing that kind of obstruction they had one trial that met the endpoint and one that didn't. So that mixed result is really what caused the pressure on the stock today. And this of course coming after Regeneron came to if you will save the day and took 23andMe out of bankruptcy recently. So they'd really gotten a bump in their stock because of that and now just kind of washed away and hitting a four-year low today. And Ange, why does this matter more for Regeneron than Sanofi? Yeah, Regeneron has had a little bit of questions surrounding it. Um, you know, some of the uh, analysts did uh, have looked at its pipeline and that's been sort of where the pressure's coming from. We saw some downgrades today just on this news. RBC and Wells Fargo punishing that stock because of the, the news today. Regeneron doesn't have any near term blockbusters and this was supposed to essentially be it. It's important to note that they already are working with Sanofi on a different product that did hit, that has been on the market. Dupixent, and it did get approved for COPD last year. That drug brings in about 14 billion and so this was looking to be sort of on the same range. Uh, even though that drug does address a number of other diseases but it could have been another blockbuster for Regeneron and now without that their near term pipeline is in question. Ange, thanks so much, appreciate it. Have a great weekend. You too.
Yahoo
5 days ago
- Business
- Yahoo
Regeneron stock sinks over trial data for smoker's lungs drug
Regeneron Pharmaceuticals (REGN) shares sank in Friday trading after the company published disappointing drug trial results for a treatment on a condition called smoker's lungs. The drug was co-developed with Sanofi (SNY, Yahoo Finance senior health reporter Anjalee Khemlani comes on Market Domination Overtime to speak more on this. Regeneron has put up a bid to acquire genetic testing firm 23andMe (ME) after the company filed for bankruptcy. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Trump admin. cancels Moderna bird fu vaccine contract
The Trump administration has canceled a contract with Moderna (MRNA) worth hundreds of millions of dollars. The contract was supposed to help Moderna develop a vaccine for humans to defend against bird flu. Yahoo Finance Senior Health Care Reporter Anjalee Khemlani reports the details in the video above. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-05-2025
- Health
- Yahoo
4 health insurance options to explore if you're unemployed
Where should you turn to for health insurance coverage if you decide to quit your job or are laid off? Yahoo Finance senior health reporter Anjalee Khemlani explores four core opportunities for healthcare plans while unemployed, including COBRA, Medicaid, and the Children's Health Insurance Program (CHIP). To watch more expert insights and analysis on the latest market action, check out more Wealth here.
